Clinical Trial Update: Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease [Phase 3]

View source ↗

Summary

Open-label extension study update for 23 mg donepezil sustained-release in moderate to severe Alzheimer's disease; study completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Donepezil SR 23 mg (donepezil)

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-06-19